Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial-Reference-Cited by-同舟云学术

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Published:2013-01-29 Issue:2 Volume:73 Page:349-356
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

McInnes Iain B,Sieper Joachim,Braun Jürgen,Emery Paul,van der Heijde Désirée,Isaacs John D,Dahmen Georg,Wollenhaupt Jürgen,Schulze-Koops Hendrik,Kogan Joseph,Ma Shenglin,Schumacher Martin M,Bertolino Arthur P,Hueber Wolfgang,Tak Paul P

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference39 articles.

1. Psoriatic arthritis: epidemiology, clinical features, course, and outcome;Gladman;Ann Rheum Dis,2005

2. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study;Zachariae;Acta Derm Venereol,2002

3. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death;Gladman;Arthritis Rheum,1998

4. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis;Rahman;J Rheumatol,2001

5. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs;Cantini;Rheumatology (Oxford),2008

Cited by 297 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials;Joint Bone Spine;2024-05

2. Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis;Advances in Rheumatology;2024-03-21

3. Secukinumab after first-line tumor necrosis factor-alpha inhibitor therapy in psoriatic arthritis: A real-world retrospective cohort study;Archives of Rheumatology;2024-01-31

4. The Saudi consensus recommendations for the management of psoriatic arthritis (2023);Clinical Rheumatology;2024-01-13

5. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis;Frontiers in Immunology;2023-11-29